{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:31:11Z","timestamp":1788957071901,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015696","name":"NATIONAL HEALTH INSURANCE SERVICE ILSANHOSPITAL","doi-asserted-by":"publisher","award":["NHIMC-2023-CR-017"],"award-info":[{"award-number":["NHIMC-2023-CR-017"]}],"id":[{"id":"10.13039\/501100015696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00198-023-06889-2","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:01:46Z","timestamp":1692410506000},"page":"2059-2067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-1956","authenticated-orcid":false,"given":"Namki","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-580X","authenticated-orcid":false,"given":"Sungjae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-183X","authenticated-orcid":false,"given":"Seunghyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"issue":"4","key":"6889_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jocd.2019.07.006","volume":"22","author":"K Krohn","year":"2019","unstructured":"Krohn K, Schwartz EN, Chung YS, Lewiecki EM (2019) Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. J Clin Densitom 22(4):501\u2013505. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.006","journal-title":"J Clin Densitom"},{"issue":"10","key":"6889_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108\u20131112. https:\/\/doi.org\/10.1001\/archinte.164.10.1108","journal-title":"Arch Intern Med"},{"issue":"4","key":"6889_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.bone.2007.11.018","volume":"42","author":"L Pothuaud","year":"2008","unstructured":"Pothuaud L, Carceller P, Hans D (2008) Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 42(4):775\u2013787. https:\/\/doi.org\/10.1016\/j.bone.2007.11.018","journal-title":"Bone"},{"issue":"3","key":"6889_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jocd.2017.06.019","volume":"20","author":"E Shevroja","year":"2017","unstructured":"Shevroja E, Lamy O, Kohlmeier L, Koromani F, Rivadeneira F, Hans D (2017) Use of trabecular bone score (TBS) as a complementary approach to dual-energy X-ray absorptiometry (DXA) for fracture risk assessment in clinical practice. J Clin Densitom 20(3):334\u2013345. https:\/\/doi.org\/10.1016\/j.jocd.2017.06.019","journal-title":"J Clin Densitom"},{"key":"6889_CR5","unstructured":"US Food and Drug Administration (2016) Indications for Use, TBS iNsight. Available at: https:\/\/www.accessdata.fda.gov\/ cdrh_docs\/pdf15\/K152299.pdf"},{"key":"6889_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","volume":"96","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyce RW, Li X, Ke HZ (2017) Effects of sclerostin antibodies in animal models of osteoporosis. Bone 96:63\u201375. https:\/\/doi.org\/10.1016\/j.bone.2016.10.019","journal-title":"Bone"},{"issue":"1","key":"6889_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41574-020-00426-5","volume":"17","author":"EG Estell","year":"2021","unstructured":"Estell EG, Rosen CJ (2021) Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 17(1):31\u201346. https:\/\/doi.org\/10.1038\/s41574-020-00426-5","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"6889_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"6889_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"9","key":"6889_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: Bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34(9):1597\u20131608. https:\/\/doi.org\/10.1002\/jbmr.3735","journal-title":"J Bone Miner Res"},{"issue":"3","key":"6889_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update. J Clin Endocrinol Metab 105(3):587\u2013597. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6889_CR12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1359\/jbmr.1997.12.8.1316","volume":"12","author":"J Hanson","year":"1997","unstructured":"Hanson J (1997) Standardization of femur BMD. J Bone Miner Res 12(8):1316\u20131317. https:\/\/doi.org\/10.1359\/jbmr.1997.12.8.1316","journal-title":"J Bone Miner Res"},{"issue":"3","key":"6889_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","volume":"18","author":"BC Silva","year":"2015","unstructured":"Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD (2015) Fracture risk prediction by Non-BMD DXA measures: the 2015 ISCD official positions part 2: Trabecular bone score. J Clin Densitom 18(3):309\u2013330. https:\/\/doi.org\/10.1016\/j.jocd.2015.06.008","journal-title":"J Clin Densitom"},{"issue":"2","key":"6889_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10(2):150\u2013161. https:\/\/doi.org\/10.1002\/pst.433","journal-title":"Pharm Stat"},{"issue":"4","key":"6889_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.11005\/jbm.2021.28.4.317","volume":"28","author":"C Jeong","year":"2021","unstructured":"Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH (2021) Effect of romosozumab on trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. J Bone Metab 28(4):317\u2013323. https:\/\/doi.org\/10.11005\/jbm.2021.28.4.317","journal-title":"J Bone Metab"},{"issue":"7","key":"6889_CR16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00198-014-2703-8","volume":"25","author":"C Senn","year":"2014","unstructured":"Senn C, G\u00fcnther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25(7):1945\u20131951. https:\/\/doi.org\/10.1007\/s00198-014-2703-8","journal-title":"Osteoporos Int"},{"issue":"2","key":"6889_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","volume":"29","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D (2018) Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int 29(2):323\u2013328. https:\/\/doi.org\/10.1007\/s00198-017-4304-9","journal-title":"Osteoporos Int"},{"issue":"5","key":"6889_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00774-021-01226-1","volume":"39","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Arita K, Murota E, Hiratsuka S, Fujita R, Ishizu H, Asano T, Takahashi D, Takahata M, Iwasaki N (2021) Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients. J Bone Miner Metab 39(5):868\u2013875. https:\/\/doi.org\/10.1007\/s00774-021-01226-1","journal-title":"J Bone Miner Metab"},{"issue":"10102","key":"6889_CR19","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6","journal-title":"Lancet"},{"issue":"5","key":"6889_CR20","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"issue":"1","key":"6889_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00198-017-4273-z","volume":"29","author":"JT Schousboe","year":"2018","unstructured":"Schousboe JT, Vo TN, Langsetmo L, Taylor BC, Kats AM, Schwartz AV, Bauer DC, Cauley JA, Ensrud KE (2018) Predictors of change of trabecular bone score (TBS) in older men: results from the osteoporotic fractures in Men (MrOS) study. Osteoporos Int 29(1):49\u201359. https:\/\/doi.org\/10.1007\/s00198-017-4273-z","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06889-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T09:02:30Z","timestamp":1700038950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06889-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6889"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06889-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board of Severane Hospital (IRB No. 4\u20132022-0273).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yumie Rhee has received honorarium from Amgen. Yumie Rhee has been an investigator for Amgen, Kyowa Kirin, Hanmi, Dongook, Donaga ST and Dawoon. Namki Hong, Sungjae Shin, Seounghyun Lee declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}